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Etidronate is an oral bisphosphonate compound that is
known to reduce bone resorption through the inhibition of
osteoclastic activity. The efficacy of etidronate for involutional
(postmenopausal and senile) and glucocorticoid-induced osteo-
porosis, as well as that for other skeletal diseases, was re-
viewed in Japanese patients. Cyclical etidronate treatment (200
mg or 400 mg/day for 2 weeks about every 3 months) in-
creases the lumbar bone mineral density (BMD) in patients
with involutional osteoporosis and prevents incident vertebral
fractures in patients with glucocorticoid-induced osteoporosis.
The losses of the lumbar BMD in patients with liver cirrhosis
and the metacarpal BMD in hemiplegic patients after stroke
are prevented, and the lumbar BMD is possibly increased,
preventing fragile fractures in adult patients with osteogenesis
imperfecta type I. Furthermore, proximal bone resorption
around the femoral stem is reduced and some complications
may be prevented in patients who undergo cementless total hip
arthroplasty. Oral etidronate treatment may also help to
transiently relieve metastatic cancer bone pain followed by a
decrease in abnormally raised bone resorption in patients with
painful bone metastases from primary cancer sites, such as the
lung, breast and prostate. Thus, oral etidronate treatment is
suggested to be efficacious for osteoporosis, as well as other
skeletal diseases associated with increased bone resorption, in
Japanese patients. Randomized controlled trials needed to be
conducted on a large number of patients to confirm these
effects.
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INTRODUCTION
Etidronate is an oral bisphosphonate compound
that is known to reduce bone resorption through
the inhibition of osteoclastic activity, and has been
widely used for the treatment of osteoporosis.
According to the results of a meta-analysis of
randomized controlled trials in foreign countries
to test the efficacy of etidronate treatment for oste-
oporosis in postmenopausal women,
1 etidronate
treatment reduced vertebral fractures (relative risk
[RR]: 0.60), but had no effect on non-vertebral
fractures (RR: 1.00). Etidronate, relative to a con-
trol, increased the bone mineral density (BMD) by
4.27% in the lumbar spine, 2.19% in the femoral
neck, and 0.97% in the total body after 3 years of
treatment. Thus, the efficacy of etidronate treat-
ment for vertebral fractures and in increasing the
lumbar and femoral neck BMD in postmenopausal
women with osteoporosis has been established.
However, the skeletal effects of etidronate in
postmenopausal women with osteoporosis have
been demonstrated to be less than those of nitr-
ogen-containing bisphosphonates.
2
With regard to glucocorticoid-induced osteopo-
rosis (GIO), a randomized controlled trial in for-
eign countries
3 showed that etidronate treatment
reduced vertebral fractures (RR: 0.57), but this
effect was not statistically significant. Recently,
however, a meta-regression analysis of the effect
of bisphosphonates for GIO
4 showed no signifi-
cant difference in the efficacy of etidronate and
nitrogen-containing bisphosphonates with respect
to the lumbar BMD. Thus, unlike the case for oste-
oporosis in postmenopausal women, the efficacy
of etidronate for GIO with respect to the BMD has
been confirmed to be similar to that of nitrogen-
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containing bisphosphonates.
In Japan, etidronate has been used, not only for
osteoporosis, but also for other skeletal diseases
associated with increased bone resorption. In this
paper, the efficacy of etidronate treatment for in-
volutional (postmenopausal and senile) and glu-
cocorticoid-induced osteoporosis, as well as that
for other skeletal diseases, was reviewed in Japa-
nese patients.
EFFICACY OF ORAL ETIDRONATE FOR
SKELETAL DISEASES IN JAPAN
Efficacy for involutional osteoporosis
It is known that both early and late postmen-
opausal Japanese women usually show a high
bone turnover.
5 Thus, anti-resorptive agents, such
as bisphosphonates, are expected to be efficacious
for osteoporosis in elderly women. Fujita et al.
6
evaluated the therapeutic effects of cyclical etid-
ronate treatment on the lumbar BMD and the
incidence of vertebral fractures in 414 patients
with involutional osteoporosis in a controlled
double-blind trial using 1 -hydroxyvitamin D α 3
(alfacalcidol) as a control. Cyclical etidronate treat-
ment (200 mg and 400 mg/day for 2 weeks every
12 weeks) for 48 weeks increased the lumbar BMD
by 2.4% and 3.4%, respectively, in patients with
involutional osteoporosis, while it was sustained
by alfacalcidol (1μg/day, 0.5% decrease). Cyclical
etidronate treatment significantly increased the
lumbar BMD compared with alfacalcidol by de-
creasing the serum alkaline phosphatase and
osteocalcin and urinary hydroxyproline/creatin-
ine and calcium/creatinine levels. The incidences
of vertebral fractures during the 48 weeks after
initiation of treatment were 6.9% and 5.4% for 200
mg and 400 mg cyclical etidronate, respectively,
and 15.5% for alfacalcidol, with a significant dif-
ference between the 400 mg cyclical etidronate
and alfacalcidol treatments. These results suggest
that cyclical etidronate treatment may be effective
for increasing the lumbar BMD and preventing
vertebral fractures in patients with involutional
osteoporosis.
The efficacy of combined treatment with cyclical
etidronate and vitamin D3 or vitamin K2 in post-
menopausal women with osteoporosis has also
been reported. It has been established in Japan
that treatment with alfacalcidol slightly reduces
bone turnover, sustains the lumbar BMD and
prevents vertebral fractures in postmenopausal
women with osteoporosis,
7 while menatetrenone
(vitamin K2) enhances γ-carboxylation of bone
glutamic acid residues and secretion of osteo-
calcin, sustains the lumbar BMD and prevents
osteoporotic fractures in patients with osteopo-
rosis.
8 Shiota et al.
9 showed in a randomized con-
trolled study conducted on 40 postmenopausal
women with osteoporosis that 2 years of treat-
ment with cyclical etidronate (200 mg/day for 2
weeks every 12 weeks) plus alfacalcidol (0.5 μg/
day) and calcium lactate (2g/day) was more
effective in increasing the lumbar BMD and
preventing vertebral fractures than treatment with
alfacalcidol and calcium lactate alone. Iwamoto et
al.
10 showed in an open-labeled randomized study
conducted on 40 postmenopausal women with
osteoporosis that one year of combined treatment
with cyclical etidronate (200 mg/day for 2 weeks
every 3 months) and alfacalcidol (1 μg/day) was
more useful than treatment with cyclical etidro-
nate alone for increasing the lumbar BMD, due to
a more marked reduction in the level of urinary
cross-linked N-terminal telopeptide of type I col-
lagen (NTX). Iwamoto et al.
11 also showed in a
prospective study conducted on 100 postmen-
opausal women with osteoporosis that 2 years of
combined treatment with cyclical etidronate (200
mg/day for 2 weeks every 3 months) and menate-
trenone (45 mg/day) might be more efficacious in
the prevention of incident vertebral fractures than
the single treatment with cyclical etidronate.
These results suggest the efficacy of the combined
treatment of cyclical etidronate with active
vitamin D3 or vitamin K2 in increasing the lumbar
BMD or preventing vertebral fractures, respec-
tively, in postmenopausal women with osteopo-
rosis.
Efficacy for inflammatory diseases and GIO
Osteoclastic activation and the destruction of
cartilage and bone are observed in patients with
rheumatoid arthritis (RA). Hasegawa et al.
12
examined the efficacy of 72 weeks of treatmentOral Etidronate and Skeletal Diseases
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with cyclical etidronate (400 mg/day for 2 weeks
every 12 weeks) for osteoporosis, bone resorption,
inflammation and joint destruction in 63 patients
with RA. Cyclical etidronate treatment reduced
the urinary deoxypyridinoline and serum interleu-
kin-6 levels and inhibited progression of the
Larsen damage score for fingers, as based on
radiographic images, suggesting that etidronate
treatment is effective in inhibiting bone resorption
and joint destruction in patients with RA.
Glucocorticoids exert effects on calcium metabo-
lism, leading to accelerated osteoporosis and an
increased incidence of fractures. Sambrook
13 sug-
gests that glucocorticoids affect bone through
multiple pathways, influencing both bone forma-
tion and bone resorption. In particular, postmen-
opausal women receiving glucocorticoid are at the
greatest risk of rapid bone loss and consequently,
fractures, and should be actively considered for
prophylactic treatment. With early therapy, the
bone loss associated with glucocorticoid treatment
can be effectively prevented or reversed. Based
upon available evidence, the drug of choice for
such prophylaxis has been a bisphosphonate, fol-
lowed by a vitamin D metabolite or hormone
replacement.
Several studies have shown the efficacy of
etidronate treatment for GIO in Japan. Tanaka and
Oshima
14 investigated the efficacy of 2 years of
treatment with cyclical etidronate (200 mg/day for
2 weeks every 3 months) in preventing the verte-
bral fractures caused by GIO in 103 patients with
collagen diseases, including rheumatoid arthritis,
and showed that this treatment significantly
reduced the risk of vertebral fractures (Odd's ratio
0.02). They also showed a therapeutic effect of
cyclical etidronate on GIO, focusing on the in-
cidence of new vertebral fractures, in 136 patients
with collagen diseases other than rheumatoid ar-
thritis.
15 The incidence of vertebral fractures dur-
ing the 2-year study period was significantly
reduced in the etidronate treatment groups (11%
vs. 31% in the non-treatment group), suggesting
the efficacy of cyclical etidronate treatment in pre-
venting vertebral fractures in patients with GIO.
Sato et al.
16 conducted a 3-year randomized
study on 102 patients with connective tissue dis-
ease, who had taken more than 7.5 mg of pre-
dnisolone daily, for at least 90 days, to test the
efficacy of cyclical etidronate treatment for GIO.
Three years of treatment with cyclical etidronate
(200 mg/day for 2 weeks every 3 months) plus 3
g calcium lactate and 0.75μg alfacalcidol daily
significantly increased the lumbar BMD by 4.8%
compared to treatment with calcium lactate and
alfacalcidol alone (only 0.4% increase), and pre-
vented vertebral fractures. These results suggest
that cyclical etidronate may be beneficial in in-
creasing the lumbar BMD and preventing verte-
bral fractures in patients with GIO.
A few small studies have shown a preventative
effect of etidronate against bone loss in patients
receiving high-dose glucocorticoid. Fujita et al.
17
showed that 3 months of treatment with etidro-
nate (200 mg/day only for 2 weeks) reduced bone
resorption and the natural progression of oste-
oporosis associated with aging or menopause in
patients with nephritis. Nakayamada et al.
18 also
assessed the efficacy of 12 months of treatment
with cyclical etidronate (200 mg/day for 2 weeks
every 3 months) and alfacalcidol (1μg/day) in
preventing glucocorticoid-induced bone loss in
patients with autoimmune diseases, who had
started high-dose glucocorticoid therapy. The per-
centage change in the lumbar BMD during a
12-month period was -4.5% in the etidronate plus
alfacalcidol group and -10.3% in the alfacalcidol
alone group, with a significant difference between
the two groups. The respective changes in the
femoral neck BMD were + 2.3% and -2.5%, with
a significant difference between the two groups.
These results suggest that cyclical etidronate may
have the potential to prevent the high-dose gluco-
corticoid-induced bone loss in patients with sys-
temic autoimmune diseases.
Efficacy for disuse osteoporosis and bone loss
after cessation of exercise (decreased physical
activity)
A few studies have demonstrated the efficacy of
etidronate treatment in osteoporosis induced by
disability such as hemiplegia after a stroke. A
significant reduction in the BMD was observed in
the hemiplegic extremities of chronic stroke
patients, which correlated with the degrees of
paralysis and vitamin D deficiency due to mal-
nutrition. Sato et al.
19 showed in a randomizedJun Iwamoto, et al.
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placebo-controlled 56-week study conducted on
98 hemiplegic patients following stroke that 56
weeks of cyclical etidronate treatment (400 mg/
day for 2 weeks every 14 weeks) did not only
retard the immobilization-induced loss of the
metacarpal BMD by decreasing the serum pyri-
dinoline cross-linked carboxyterminal telopeptide
of type I collagen (1CTP) level, but also decreased
the serum parathyroid hormone level and im-
proved hypercalcemia, which was followed by an
increased serum 1,25-dihydroxyvitamin D level.
These results suggest that cyclical etidronate
treatment may retard the BMD loss in hemiplegic
stroke patients as it decreases the serum calcium
level through the inhibition of bone resorption
and causes a subsequent increase in the serum
1,25-dihydroxyvitamin D level.
Ikai et al.
20 showed in a prospective study con-
duced on 81 postmenopausal women with hemi-
plegia after cerebrovascular accident that 3
months of treatment with etidronate (200 mg or
400 mg/day for only 2 weeks) and rehabilitation
retarded the loss of the femoral neck BMD on the
paralytic side (4.0% decrease in the treatment
group vs. 9.6% decrease in the control group) by
reducing the urinary pyridinoline and deoxy-
pyridinoline levels from those at the baseline,
especially in patients with low activities of daily
living, as evaluated by using the FIM
TM instru-
ment. These results suggest that treatment with
etidronate and increasing the activities of daily
living may be helpful to reduce bone loss in
hemiplegic disabled patients.
It is known that stopping training in terms of
decreased physical activity may result in a loss of
bone gain in exercise-trained subjects. Iwamoto et
al.
21 reported that bone gain through exercise was
lost after cessation of exercise in postmenopausal
women with osteoporosis; one or two years of
brisk walking exercise increased the lumbar BMD
from that of the baseline, but one-year cessation
of exercise after one year of exercise resulted in
its loss. However, cyclical etidronate treatment
(200 mg/day for 2 weeks every 3 months) for two
years just after cessation of 2 years of walking
exercise prevented this loss in postmenopausal
women with osteoporosis. These results suggest
the efficacy of cyclical etidtonate in preventing the
bone loss caused by decreased physical activity in
exercise-trained postmenopausal women with
osteoporosis.
Efficacy for liver-cirrhosis-induced osteopenia
It is known that liver cirrhosis induces oste-
openia.
22 An experimental study demonstrated
that liver-cirrhosis-induced osteopenia may be
attributable primarily to decreased bone forma-
tion.
23 However, the efficacy of treatment with the
anti-resorptive agent, etidronate, for osteopenia
has been reported in patients with liver cirrhosis.
Shiomi et al.
24 showed in a randomized controlled
3-year study conducted on 50 women with cir-
rhosis caused by viral hepatitis infection that the
lumbar BMD was sustained (0.6% decrease) in the
etidronate treatment (200 mg/day for 2 weeks
every 12 weeks) group, but decreased by 5.2% in
the non-treatment group. However, no significant
differences in changes in the serum osteocalcin
and 1CTP levels were observed between the two
groups. These results suggest that cyclical etidro-
nate may have the potential to prevent liver- cir-
rhosis-induced bone loss. However, urinary bone
resorption markers were not assessed in this
study. Thus, further studies are needed to clarify
the mechanism of liver-cirrhosis-induced oste-
openia and confirm the effect of etidronate treat-
ment on bone resorption in osteopenic patients
with liver cirrhosis.
Efficacy for adult osteogenesis imperfecta (OI)
OI is a heterogeneous group of genetic disor-
ders that affect the integrity of connective tissue.
The hallmark of OI is bone fragility, although
other manifestations, including osteoporosis, den-
tigenesis imperfecta, blue sclerae, easy bruising,
joint laxity and scoliosis, are also common among
OI patients. Although OI is a heritable disorder of
bone formation, resulting in bone fragility, the ac-
tivity of cancellous bone remodeling, bone resorp-
tion and/or bone turnover are also increased.
25,26
The BMD usually remains low in adults with OI;
however, very few studies have been reported on
the treatment of osteopenia in adults with OI.
A case report has described the efficacy of etid-
ronate treatment in a 36-year-old man with OI
type I, who frequently experienced fragile frac-Oral Etidronate and Skeletal Diseases
Yonsei Med J Vol. 46, No. 3, 2005
tures of the long bones of the upper and lower
extremities and back pain caused by thoracic
fragile vertebral fractures.
27 Combined treatment
with cyclical etidronate (200 mg/day for 2 weeks
every 3 months) and alfacalcidol (1μg/day, daily)
increased the lumbar BMD by 3.9% after 18
months, reduced the back pain due to thoracic
vertebral fractures and prevented new fragile ver-
tebral and non-vertebral fractures. This report
provided evidence that treatment with cyclical
etidronate and alfacalcidol may potentially be
useful for adult patients with OI type I.
Efficacy for local osteopenia after total hip arthr-
oplasty (THA)
Proximal bone resorption around the femoral
stem is one of the major complications of cement-
less THA, which possibly results in late stem
loosening and femoral fractures. Yamaguchi et
al.
28 showed in a randomized controlled study
conducted on 42 patients with osteoarthritis of the
hip joint secondary to acetabular dysplasia that 12
months of treatment with cyclical etidronate (400
mg/day for 2 weeks every 14 weeks) reduced the
BMD loss in the proximal femur after cementless
THA by decreasing the serum bone-specific alka-
line phosphatase (BAP) and urinary NTX levels,
suggesting that etidronate treatment may reduce
proximal bone resorption around the femoral
stem and help prevent some of the complications
in patients undergoing cementless THA.
Efficacy for atherogenic process
Bisphosphonates may have some anti-athero-
genic actions. Koshiyama et al.
29 prospectively ex-
amined the effect of cyclical etidronate treatment
on the carotid arterial intima-media thickness in
57 patients with type 2 diabetes associated with
osteopenia. One year of treatment with cyclical etid-
ronate treatment (200 mg/day for 2 weeks every
3 months) decreased the intima-media thickness by
0.038 mm, which was significantly different from
the change (0.023 mm increase) in the 57 control
subjects, suggesting an anti-atherogenic action of
etidronate at least in type 2 diabetes. However,
the exact mechanisms by which etidronate exerts
its anti-atherogenic effect remain uncertain.
Efficacy for bone pain caused by cancer bone
metastasis
Bone is a common site of metastasis in patients
with advanced cancer. Bone metastasis frequently
causes, not only skeletal destruction and patho-
logical fractures, but also pain, and is commonly
observed in patients with breast, prostate or lung
cancer. In general, metastatic breast and lung
cancers are osteolytic and prostate cancers are
osteosclerotic. Bone metastasis is a cause of mor-
bidity and mortality in patients with cancer, and
is associated with a poor prognosis. Pain control
is a crucial factor in determining the quality of life
of patients during the last months of their lives.
Since both osteolytic and mixed (osteolytic/osteo-
sclerotic) types of bone metastases appear to show
increased bone remodeling activity (bone resorp-
tion),
30,31 drugs affecting bone metabolism, such as
anti-resorptive agents, bisphosphonates may be
effective for pain control in patients with osteoly-
tic and mixed types of bone metastasis.
Oral bisphosphonates have not been used rou-
tinely in the treatment of cancer bone metastasis
because of their low bioavailability. However, oral
bisphosphonates may be helpful to relieve the
pain caused by bone metastasis, if skeletal events,
including bone pain, are mild without hypercal-
cemia. In Japan, the efficacy of oral bisphospho-
nates for the pain caused by cancer bone metas-
tasis has not been established. The short-term
effect of oral etidronate treatment on the mild
metastatic cancer bone pain was examined in
patients with lung, breast or prostate cancer (un-
published data). Twenty-three patients with lung,
breast or prostate cancer were recruited: 13 with
pain caused by bone metastasis from the primary
cancer site; lung (n=6), breast (n=3) or prostate
(n=4) (bone metastasis [M] group), and 10 with
primary cancer of the lung (n=4), breast (n=4) or
prostate (n=2), with no such evidence of skeletal-
related events (non-bone-metastasis [non-M]
group). The type of bone metastasis was osteolytic
in patients with breast or lung cancer, and mixed
(osteolytic/osteosclerotic) in patients with prostate
cancer. None of the patients in the M group either
needed morphine for pain relief or had hypercal-
cemia. During the study, the subjects continued
taking nonsteroidal anti-inflammatory drugs asJun Iwamoto, et al.
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before the study. The levels of serum BAP and
urinary NTX were significantly higher in the M
group than in the non-M group (Table 1). Treat-
ment with oral etidronate (400 mg/day for 2
weeks) in the M group patients reduced bone pain
(evaluated by the face scale score, which is ar-
ranged in decreasing order of mood, and num-
bered from 1-10, with 1 representing the most
positive mood [painless] and 10 representing the
most negative mood [painful]) and was followed
by a decrease in the urinary NTX level over 3
months (Fig. 1 and Table 2). The lack of significant
changes in the serum BAP levels may be ex-
plained by the slower response of serum BAP to
bisphosphonates than that of urinary NTX.
32 It
was surmised that a reduction in the serum BAP
level would be observed after at least 3 months of
etidronate treatment. These results suggested that
patients with painful bone metastases from pri-
mary cancer sites, such as the lung, breast and
prostate, had a higher bone turnover than those
with no evidence of skeletal events, and that oral
etidronate treatment might be helpful relieve
metastatic cancer bone pain followed by a de-
crease in abnormally raised bone resorption.
However, because this study was not a rando-
mized placebo-controlled trial, our conclusion on
the efficacy of oral etidronate treatment for meta-
static cancer bone pain might, therefore, be weak,
so further studies will be needed to confirm our
results.
CONCLUSIONS
The efficacy of oral etidronate treatment for
Table 1. Characteristics of Study Subjects and Levels of Biochemical Markers and Face Scale Score at Baseline
M group non-M group p value
Number
Male/Female
Age (years)
Height (m)
Body weight (kg)
Serum calcium (mg/dl)
Serum phosphorus (mg/dl)
Serum BAP (IU/l)
Urinary NTX (nmol BCE/mmol Cr)
Face scale score
13
10/3
66.5±10.4
1.60±0.07
54.0±8.3
9.0±0.3
3.1±0.6
52.0±33.0
108.2±45.6
5.9±1.3
10
6/4
65.7±6.5
1.62±0.08
58.2±6.6
9.2±0.3
3.2±0.5
27.2±9.8
42.0±8.5
ns
ns
ns
ns
ns
<0.05
<0.01
Data are expressed as mean±SD.
Data comparison between the two groups was performed by unpaired t-test.
BAP, bone-specific alkaline phosphatase; NTX, cross-linked N-telopeptides of type I collagen.
ns, not significant; M group, bone metastasis group; non-M group, non-bone-metastasis group.
Table 2. Changes in Levels of Biochemical Markers with Treatment in M Group
Week 0 Week 12 One-way ANOVA
Serum calcium (mg/dl)
Serum phosphorus (mg/dl)
Serum BAP (IU/l)
Urinary NTX (nmol BCE/mmol Cr)
9.0±0.3
3.1±0.6
52.0±33.0
108.2±45.6
9.0±0.4
3.1±0.6
52.9±38.8
100.7±45.3
ns
ns
ns
<0.05
Data are expressed as mean ± SD.
The significance of the longitudinal changes in biochemical markers was determined by one-way ANOVA with repeated measurements.
BAP, bone-specific alkaline phosphatase; NTX, cross-linked N-telopeptides of type I collagen.
ns, not significant; M group, bone metastasis group.Oral Etidronate and Skeletal Diseases
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osteoporosis, as well as other skeletal diseases,
associated with increased bone resorption has
been demonstrated in Japan. Cyclical etidronate
treatment increases the lumbar BMD in patients
with involutional osteoporosis and reduces the
vertebral fractures in patients with GIO. There is
some evidence indicating the efficacy of cyclical
etidronate for the BMD loss in patients with liver
cirrhosis, bone fragility in adult patients with
osteogenesis imperfecta type I, and proximal bone
resorption around the femoral stem in patients
undegoing cementless THA. Oral etidronate treat-
ment may also transiently relieve the metastatic
cancer bone pain in patients with painful bone
metastases from primary cancer sites, such as the
lung, breast and prostate. Randomized controlled
studies conducted on a large number of patients
will be needed to confirm these effects.
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